Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301419 | 0.84 | CHEK1 (0.42) | CHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL31301361 | 0.82 | SCN10A (0.51) | CHEK1SCN10ASCN2A | |
| SCHEMBL31020328 | 0.82 | SCN10A (0.58) | CHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL24994317 | 0.81 | DHODH (0.51) | DHODHCHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL31118894 | 0.80 | CHEK1 (0.51) | CHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL319106 | 0.80 | CHEK1 (0.50) | CHEK1SCN10AMCL1PDE10ALDHA | |
| SCHEMBL4820848 | 0.79 | NPC1 (0.46) | DHODHCHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL31301550 | 0.78 | RAB9A (0.54) | CHEK1SCN10ASCN2A | |
| SCHEMBL24499968 | 0.78 | CHEK1 (0.73) | CHEK1SCN10ASCN2AMCL1 | |
| SCHEMBL31143095 | 0.78 | PIM1 (0.40) | CHEK1SCN10ASCN2AMCL1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | DHODH 126/4885CHEK1 1982/4885SCN10A 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.